Gelonghui May 24 丨 Hehuang Pharmaceutical (00013slotwildwestgoldmegaways.HK) today announced that it will be held in Chicago, Illinois, USA from May 31 to June 4, 2024slotwildwestgoldmegawaysThe latest and updated data from several studies on compounds independently developed by Hutchison Pharmaceutical were released at the 2024 Annual Meeting of the American Society of Clinical Oncology ("ASCO").
Following the release of preliminary data from the FRUTIGA Phase III study of fruquintinib for the second-line treatment of gastric cancer at the ASCO Plenary Series session held in February 2024slotwildwestgoldmegawaysFurther updated efficacy data and quality of life data for key subgroups of the study will be released at this year's ASCO Annual Meeting. In addition, further data from the FRESCO and FRESCO-2 colorectal cancer phase III studies, sufantinib combination therapy in the treatment of small cell lung cancer, and preliminary clinical data from the ERK1/2 inhibitor HMPL-295 will also be announced at the conference.